Role of imaging in prostate cancer;Apport de l'imagerie dans le cancer de prostate

Progres en Urologie

Volumn 13, Issue 5, 2003, Pages 843-884

  Descotes, J L ^b   Hubert, J ^b   Rouviere O ^b   Artignan, X ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DOPPLER FLOWMETRY; ECHOGRAPHY; HUMAN; LYMPH NODE DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE CARCINOMA; RADIODIAGNOSIS; TRANSRECTAL ULTRASONOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROSTATE TUMOR; REVIEW;

HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROSTATIC NEOPLASMS;

EID: 12144251621     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (206)

1. AARNINK R. G., BEERLAGE H. P., DE LA ROSETTE JEAN J.J. , DEBRUYNE F., HESSEL W.. Transrectal ultrasoud of the prostate. Innovations and future applications. J. Urol., 1998, 159, 1568-1579.
2. ADUSUMILLI S, PRETORIUS ES. Magnetic resonance imaging of prostate cancer. Semin. Urol. Oncol., 2002 , 20, 192-210.
3. BADER P, BURKHARD FC, MARKWALDER R, STUDER UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J. Urol., 2002, 168, 514-518.
4. BALAJI K.C. FAIR W., FELEPPA E. J., PORTER C. R., TSAI H., LIU T., KALISZ A., URBAN S., GILLESPIE J. Role of Advanced 2 And 3-Dimensional Ultrasound For Detecting Prostate Cancer. J. Urol., 2002 , 168, 2422-2425.
5. BALTER JM, SANDLER HM, LAM K, BREE RL, LICHTER AS, TEN HAKEN RK. Measurement of prostate movement over the course of routine radiotherapy using implanted markers. Int J Radiat Oncol Biol Phys 1995, 1; 31, 113-118
6. BARENTSZ JO, ENGELBRECHT M, JAGER GJ, WITJES JA, DE LAROSETTE J, VAN DER SANDEN BPJ, HUISMAN HJ, HEERSCHAP A. Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J. Magn. Reson. Imaging., 1999, 10, 295-304.
7. BARTOLOZZI C, CROCETTI L, MENCHI I, ORTORI S, LENCIONI R.: Endorectal magnetic resonance imaging in local staging of prostate carcinoma. Abdom imaging 2001, 26, 111-122.
8. BATES TS, GILLATT DA, CAVANAGH PM, SPEAKMAN M. A comparison of endorectal magnetic resonance imaging and transrectal ultrasonography in the local staging of prostate cancer with histopathological correlation. Br. J. Urol., 1997, 79, 927-932.
9. BELLIN MF, BEIGELMAN C, PRECETTI-MOREL S. Iron oxide-enhanced MR lymphography: initial experience. Eur. J. Radiol., 2000, 34, 257-264.
10. BELLIN MF, LEBLEU L, MERIC JB. Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography. Abdom. Imaging., 2003, 28, 155-163.
11. BELLON J, WALLNER K, ELLIS W, RUSSELL K, CAVANAGH W, BLASKO J. Use of pelvic CT scanning to evaluate pubic arch interference of transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys., 1999, 1, 43, 579-581.
12. BERNSTEIN MR, CANGIANO T, D'AMICO A, KENNEDY E, HARDY C, WHITTINGTON RD, TOMASZEWSKI JE, SCHNALL MD, WEIN AJ, MALKOWICZ SB. Endorectal coil magnetic resonance imaging and clinicopathologic findings in T1c adenocarcinoma of the prostate. Urol. Oncol. 2000, 1, 5, 104-107.
13. BEYERSDORFF D, TAUPITZ M, WINKELMANN B, FISCHER T, LENK S, LOENING SA, HAMM B. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology, 2002, 224, 701-706.
14. BEZZI M, KRESSEL HY, ALLEN KS. Prostatic carcinoma: staging with imaging at 1.5T. Radiology, 1988, 169, 339-346.
15. BIONDETTI PR, LEE J, LING D, CATALONA WJ. Clinical Stage B prostate carcinoma : staging with MR imaging. Radiology 1987, 162, 325-329.
16. BLUTE ML, BERGSTRALH EJ, PARTIN AW, WALSH PC, KATTAN MW, SCARDINO PT, MONTIE JE, PEARSON JD, SLEZAK JM, ZINCKE H. Validation of partin tables for predicting pathological stage of clinically localized prostate cancer. J. Urol., 2000, 164, 1591-1595.
17. BOSTWICK DG, QIAN J, SCHLESINGER C. Contemporary pathology of prostate cancer. Urol. Clin. North Am., 2003, 30, 181-207.
18. CAGLAR M, TUNCEL M.: Preserved value of bone scintigraphy for the detection of skeletal metastases in prostate cancer patients with low prostate-specific antigen levels: effect of hormonal therapy and poor histologie differentiation. Clin. Nucl. Med., 2002, 27, 532-533.
19. CARROL CL, SOMMER FG, MCNEAL JE, STAMEY TA. The abnormal prostate : MR imaging at 1.5 T with histopathologic correlation. Radiology, 1987, 163, 521-525.
20. CARTER HB, BREM RF, TEMPANY CM, YANG A, EPSTEIN JI, WALSH PC, ZERHOUNI EA. Nonpalpable prostate cancer : detection with MR imaging. Radiology, 1991, 178, 523-525.
21. CHAUTARD D., CELLIER P., DALIFARD I., PABOT du CHATELARD P., CHAUSSIS F., VIELLE B., SORET J.Y., PASSAGOT J., COURTE C., DAVER A. Suivi biologique du cancer de la prostate traité par radiothérapie exclusive : valeur pronostique du PSA pré-thérapeutique, du PSA Nadir et de la demi-vie du PSA. Prog Urol, 2002, 12, 421-428.
22. CHEFCHAOUNI MC, FLAM T, CORNUD F, THIOUNN N, BELIN X, DESLIGNERES S, ZERBIB M, MOREAU JL, DEBRE B. Résultats de l'IRM endorectales dans la stadification des cancer de prostate Corrélation avec les pièces de prostatectomie radicale A propos of 47 cases. J Urol (Paris), 1996, 102, 51-55.
23. CHELSKY MJ, SCHNALL MD, SEIDMON EJ, POLLACK HM. Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. J Urol 1993, 150, 391-395.
24. CHENG GC, CHEN MH, WHITTINGTON R, MALKOWICZ SB, SCHNALL MD, TOMASZEWSKI JE, D'AMICO AV. Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA
25. CHENVEN ES, GLAZIER DB, KRISCH EB, DIAMOND SM, MARMAR JL. Evaluation of prostate volume by transrectal ultrasonography for use in a brachytherapy program. Urology, 2001, 58, 752-755.
26. CHO JY, KIM SH, LEE SE.: Peripheral hypoechoic lesions of the prostate: evaluation with color and power Doppler ultrasound. Eur. Urol., 2000, 37, 443-448.
27. CLEMENTS R .Ultrasonography of prostate cancer. Eur. Radiol., 2001, 11, 2119-2125.
28. COAKLEY F. V., HRICAK B, HEDVIGCH. , WEFER A. E., SPEIGHT J. L., KURHANEWICZ J., ROACH III M. Brachytherapy for Prostate Cancer: Endorectal MR Imaging of Local Treatment-related Changes . Radiology. 2001, 219, 817-821.
29. COAKLEY F. V., KURHANEWICZ J., LU Y., JONES K. D., SWANSON M. G., CHANG S. D., CARROLL P. R., HRICAK H. Prostate Cancer Tumor Volume: Measurement with Endorectal MR and MR Spectroscopic Imaging. Radiology, 2002, 223, 91-97.
30. COCHLIN DL, GANATRA RH, GRIFFITHS DF.: Elastography in the detection of prostatic cancer. Clin Radiol, 2002, 57, 1014-1020.
31. COMET-BATTLE J., VILANOVA-BUSQUETS J.C, SALADIE-ROIG J.M, GELABERT-MAS A., BARCELO-VIDAL C. The value of endorectal MRI in early diagnosis of prostate cancer, Eur. Urol., 2003, 44, 201-208.
32. CORNUD F, BELIN X, FLAM T, CHRETIEN Y, DESLIGNIERES S, PARAF F, CASANOVA JM, THIOUNN N, HELENON O, DEBRE B, DUFOUR B, MOREAU JF Local staging of prostate cancer by endorectal MRI using fast spin-echo sequences: prospective correlation with pathological findings after radical prostatectomy. Br J Urol. 1996, ;77, 843-850.
33. CORNUD F, BELIN X, PIRON D, CHRETIEN Y, FLAM T, CASANOVA JM, HELENON O, MEJEAN A, THIOUNN N, MOREAU JF. Color Doppler-guided prostate biopsies in 591 patients with an elevated serum PSA level: impact on Gleason score for nonpalpable lesions. Urology, 1997, 49, 709-715.
34. CORNUD F, HAMIDA K, FLAM T, HELENON O, CHRETIEN Y, THIOUNN N, CORREAS JM, CASANOVA JM, MOREAU JF. Endorectal color Doppler sonography and endorectal MR imaging features of nonpalpable prostate cancer: correlation with radical prostatectomy findings. AJR, 2000, 175, 1161-1168.
35. CORNUD F, OYEN R. : Role of imaging in the diagnosis and staging of prostatic adenocarcinomas. J Radiol. 2002 Jun;83(6 Pt 2):863-80.
36. CRUZ M, TSUDA K, NARUMI Y, KUROIWA Y, NOSE T, KOJIMA Y, OKUYAMA A, TAKAHASHI S, AOZASA K, BARENTSZ JO, NAKAMURA H. : Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging. Eur. Radiol., 2002, 12, 357-365.
37. D'AMICO A.V., TEMPANY C.M., CORMACK R., HATA N., JINZAKI M., TUNCALI K., WEINSTEIN M., RICHIE J.P.. Transperineal magnetic resonance guided. J. Urol., 2000, 164, 385-387.
38. DAHNERT WF, HAMPER UM, EGGLESTON JC, WALSH PC, SANDERS RC. Prostatic evaluation by transrectal sonography with histopathologic correlation: the echopenic appearance of early carcinoma. Radiology, 1986, 158, 97-102.
39. D'AMICO A, CORMACK R, KUMAR S, TEMPANY CM. Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer. J Endourol., 2000, 14, 367-70.
40. D'AMICO AV, CORMACK RA, TEMPANY CM. MRI-guided diagnosis and treatment of prostate cancer. N. Engl. J. Med., 2001, 8, 344, 776-777.
41. D'AMICO AV, WHITTINGTON R, MALKOWICZ SB, SCHULTZ D, SCHNALL M, TOMASZEWSKI JE, WEIN A.: Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer. J Clin Oncol. 1996, 14, 1770-1777.
42. DE JONG IJ, PRUIM J, ELSINGA PH, VAALBURG W, MENSINK HJ.: Visualization of prostate cancer with 11C-choline positron emission tomography. Eur. Urol., 2002, 42, 18-23.
43. DE LA ROSETTE J. J., AARNINK RG. New Developments in Ultrasonography for the Detection of Prostate Cancer. J. Endourol., 2001, 15, 93-104.
44. DE LA ROSETTE JJ, GIESEN RJ, HUYNEN AL, AARNINK RG, DEBRUYNE FM, WIJKSTRA H. Computerized analysis of transrectal ultrasonography images in the detection of prostate carcinoma. Br J Urol., 1995, 75, 485-491.
45. DEARNALEY DP, KHOO VS, NORMAN AR, MEYER L, NAHUM A, TAIT D, YARNOLD J, HORWICH A. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomized trial. Lancet 1999, 23, 353, 267-272
46. DEBOIS M, OYEN R, MAES F, VERSWIJVEL G, GATTI G, BOSMANS H, FERON M, BELLON E, KUTCHER G, VAN POPPEL H, VANUYT-SEL L. The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer. Int J Radiat Oncol Biol. Phys., 1999, 1,45, 857-865.
47. DEGRADO T R., COLEMAN R.E., WANG S., BALDWIN S.W. ORR M.D., ROBERTSON N. POLASCIK T.J. PRICE D.T. Synthesis and evaluation of 18 F labeled Choline as an oncologic tracer for PET : Initial findings in prostate cancer : Cancer research, 2000, 61, 110-117.
48. DIBIASE SJ, HOSSEINZADEH K, GULLAPALLI RP, JACOBS SC, NASLUND MJ, SKLAR GN, ALEXANDER RB, YU C.: Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol., Phys., 2002, 1,52, 429-438.
49. DICKIE GJ, MACFARLANE D. Strontium and samarium therapy for bone metastases from prostate carcinoma. Australas Radiol., 1999, 43, 476-479.
50. ECKERSLEY RJ, SEDELAAR JP, BLOMLEY MJ, WIJKSTRA H, DESOUZA NM, COSGROVE DO, DE LA ROSETTE JJ. Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma. Prostate 2002, 1, 51, 256-267.
51. EGAWA S, CARTER SS, WHEELER TM, SCARDINO PT. Sonographic monitoring of prostate cancer after definitive radiotherapy. Urology, 1992, 40, 230-236.
52. EL-GABRY EA, HALPERN EJ, STRUP SE, GOMELLA LG. Imaging prostate cancer: current and future applications. Oncology , 2001, 15, 325-336.
53. ELLIS WJ, BRAWER MK. The significance of isoechoic prostatic carcinoma. J Urol., 1994, 152, 2304-2307.
54. ENGELBRECHT MR, JAGER GJ, Laheij RJ, VERBEEK AL, VAN LIER HJ, BARENTSZ JO. Local staging of prostate cancer using resonance magnetic : a meta analysis. Eur. Radiol., 2002, 12 , 2294-2302 .
55. ENGELBRECHT MR, JAGER GJ, SEVERENS JL. : Patient selection for magnetic resonance imaging of prostate cancer. Eur Urol 2001 Sep;40(3):300-7.
56. ENGELHARD K, HOLLENBACH HP, DEIMLING M, KRECKEL M, RIEDL C. Combination of signal intensity measurements of lesions in the peripheral zone of prostate with MRI and serum PSA level for differentiating benign disease from prostate cancer. Eur. Radiol., 2000, 10, 1947-1953.
57. FAN X, RIVER JN, ZAMORA M, TARLO K, KELLAR K, RINKERSCHAEFFER C, KARCZMAR GS. Differentiation of nonmetastatic and metastatic rodent prostate tumors with high spectral and spatial resolution MRI. Magn. Reson. Med., 2001, 45, 1046-1055.
58. FAVAZZA T, PERKEL JA, BENNERMAN R, NSEYO U. A simple method to improve the efficiency of transrectal ultrasound guided prostate biopsy. J. Urol., 2002, 168, 1989.
59. FENELEY M. R., PARTIN A. W. Diagnosis of localized: 10 years of progress. Current Opinion in Urology, 2000, 10, 319-327.
60. FIORINO C, RENI M, BOLOGNESI A, CATTANEO GM, CALANDRINO R. Intra- and inter-observer variability in contouring prostate and seminal vesicles: implications for conformal treatment planning. Radiother Oncol 1998 ,47, 285-292
61. FLESHNER NE, O'SULLIVAN M, PREMDASS C, FAIR WR. Clinical significance of small (less than 0.2 cm3) hypocchoic lesions in men with normal digital rectal examinations and prostate-specific antigen levels less than 10 ng/mL. Urology, 1999, 53, 356-358.
62. FRANCO OE, ARIMA K, YANAGAWA M, KAWAMURA J. The usefulness of power Doppler ultrasonography for diagnosing prostate cancer histological correlation of each biopsy site. BJU 2000 85, 1049-1052.
63. FRAUSCHER F, KLAUSER A, HALPERN EJ, HORNINGER W. BARTSCH G: Detection of prostate cancer with a microbubble ultrasound contrast agent. Lancet. 2001, 9, 357, 1849-1850.
64. FRAUSCHER F, KLAUSER A, VOLGGER H, HALPERN EJ, PALLWEIN L, STEINER H, SCHUSTER A, HORNINGER W, ROGATSCH H, BARTSCH G.. Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. J. Urol., 2002, 167, 1648-1652.
65. FRAUSCHER P., HALPERN E. J., KLAUSER A. Accuracy of Gray-Scale and Color Doppler US and Serum Marker as Predictors of Prostate Carcinoma., 2002, Radiology, (223) 282-284.
66. FRAUSCHER P., KLAUSER A., HALPERN ETHAN J, HORNINGER W., BARTSCH G. Detection of prostate cancer with a microbubble ultrasound contrast agent. Ultrasound quaterly, 2002, 18, 135-142.
67. FRICKE E, MACHTENS S, HOFMANN M, VAN DEN HOFF J, BERGH S, BRUNKHORST T, MEYER GJ, KARSTENS JH, KNAPP WH, BOERNER AR. Positron emission tomography with (11)C-acetate and (18)F-FDG in prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 607-611.
68. FRITZSKE PJ, AXFORD PD, CHING VC, ROSENQUIST RW, MOORE RJ. Correlation of transrectal sonographic findings in patients with suspected and unsuspected prostatic disease. J Urol., 1983, 130, 272-274.
69. FUJII Y, HIGASHI Y, OWADA F, OKUNO T, MIZUNO H, MIZUNO H. Magnetic resonance imaging for the diagnosis of prostate cancer metastatic to bone. Br. J. Urol., 1995, 75, 54-58.
70. GELET A, CHAPELON JY, BOUVIER R, ROUVIERE O, LASNE Y, LYONNET D, DUBERNARD JM. Transrectal High-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol., 2000, 14, 519-528.
71. GEORGE B, DOUARD MC, RAIN JD. Metabolic radiotherapy: what role will it have in 2001? Cancer Radiother., 2002,6, 188-200.
72. GETTY DJ, SELTZER SE, TEMPANY CM, PICKETT RM, SWETS JA, MCNEIL BJ. Prostate cancer: relative effects of demographic, clinical, histologic, and MR imaging variables on the accuracy of staging. Radiology, 1997, 204, 471-479.
73. GIESEN RJ, HUYNEN AL, AARNINK RG, DE LA ROSETTE JJ, VD KAA C, OOSTERHOF GO, DEBRUYNE FM, WIJKSTRA H. Computer analysis of transrectal ultrasound images of the prostate for the detection of carcinoma: a prospective study in radical prostatectomy specimens. J Urol., 1995, 154, 1397-1400.
74. GILHUIJS KG, VAN DE VEN PJ, VAN HERK M. Automatic three-dimensional inspection of patient setup in radiation therapy using portal images, simulator images, and computed tomography data. Med Phys , 23, 389-399
75. GOEL MC, EVANS N, ROBERTS JG. : Re: prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy: a pilot study. J. Urol., 2000, 163, 1893-1894.
76. GRUBNIC S, VINNICOMBE SJ, NORMAN AR, HUSBAND JE. MR evaluation of normal retroperitoneal and pelvic lymph nodes. Clin. Radiol., 2002, 57, 193-200.
77. HALPERN E J., VERKH L., FORSBERG F, GOMELLA L. G., MATTREY R.P. GOLDBERG B. B. Initial Experience with Contrast-Enhanced Sonography of the Prostate. AJR, 2000 , 174 , 1575-1580.
78. HALPERN E. J. , STRUP S. E. Using Gray-Scale and Color and Power Doppler Sonography to Detect Prostatic Cancer. AJR, 2000 , 174 , 623-627.
79. HALPERN EJ, FRAUSCHER F, STRUP SE, NAZARIAN LN, O'KANE P, GOMELLA LG. Prostate: high-frequency Doppler us imaging for cancer detection. Radiology, 2002, 225,71-77
80. HALPERN ETHAN J., FRAUSCHER FERDINAND , ROSENBERG MARTIN LEONARD GOMELLA G. Directed Biopsy During Contrast-Enhanced Sonography of the Prostate. AJR, 2002 , 178 , 915-919.
81. HAMMERER P, HULAND H. Systematic sextant biopsies in 651 patients referred for prostate evaluation. J Urol., 1994, 151, 99-102.
82. HANKS GE, HANLON AL, SCHULTHEISS TE, PINOVER WH, MOVSAS B, EPSTEIN BE, HUNT MA. Dose escalation with 3D conformal treatment: five-year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 1998 ,1, 41, 501-510
83. HANLEY J, LUMLEY MA, MAGERAS GS, SUN J, ZELEFSKY MJ, LEIBEL SA, FUKS Z, KUTCHER GJ. Measurement of patient positioning errors in three-dimensional conformal radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 1997, 15, 37, 435-444
84. HARA T, KOSAKA N, KISHI H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J. Nucl. Med., 2002, 43, 187-199.
85. HARISINGHANI MG, BARENTSZ J, HAHN PF, DESERNO WM, TABATABAEI S, VAN DE KAA CH, DE LA ROSETTE J, WEISSLEDER R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J Med., 2003, 19, 348, 2491-2499.
86. HARISINGHANI MG, SAINI S, SLATER GJ, SCHNALL MD, RIFKIN MD.: MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (Combidex): preliminary observations. J. Magn. Reson. Imaging, 1997, 7, 161-163.
87. HARISINGHANI MG, SAINI S, WEISSLEDER R, HAHN PF, YANTISS RK, TEMPANY C, WOOD BJ, MUELLER PR.: MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. AJR, 1999 172, 1347-1351.
88. HARRIS RD, SCHNED AR, HEANEY JA. Staging of prostate cancer with endorectal MR imaging: lessons from a learning curve. Radiographics. 1995, 15, 813-829.
89. HATA N, JINZAKI M, KACHER D, CORMAK R, GERING D, NABAVI A, SILVERMAN SG, D'AMICO AV, KIKINIS R, JOLESZ FA, TEMPANY CM. MR imaging-guided prostate biopsy with surgical navigation software: device validation and feasibility. Radiology, 2001, 220, 263-268.
90. HAUKAAS S. Magnetic resonance imaging of the prostate. Curr. Opin. Urol., 2001, 11, 181-188.
91. HEICAPPELL R, MULLER-MATTHEIS V, REINHARDT M, VOSBERG H, GERHARZ CD, MULLER-GARTNER H, ACKERMANN R. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D- glucose. Eur. Urol. 1999, 36, 582-587.
92. HOFER C, LAUBENBACHER C, BLOCK T, BREUL J, HARTUNG R, SCHWAIGER M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur. Urol., 1999, 36, 31-35.
93. HRICAK H. Communication libre congrès RSNA 2002
94. HRICAK H. Editorial: Imaging Prostate Cancer. J. Urol., 1999, 162, 1329.
95. HRUBY G, CHOO R, KLOTZ L, DANJOUX C, MURPHY J, DEBOER G, MORTON G, RAKOVITCH E, SZUMACHER E, FLESHNER N. The role of serial transrectal ultrasonography in a 'watchful waiting' protocol for men with localized prostate cancer. BJU , 2001 , 87, 643-647.
96. IKONEN S., KIVISAARI L, TERVAHARTIALA P, VEHMAS T, TAARI K, RANNIKKO S. Prostatic MR imaging. Accuracy in differentiating cancer from other prostatic disorders. Acta Radiol., 2001, 42, 348-354.
97. ISMAIL M, GOMELLA LG. Ultrasound for prostate imaging and biopsy. Curr Opin Urol., 2001, 11, 471-477.
98. JAGER GJ, RUIJTER ET, VAN DE KAA CA, DE LA ROSETTE JJ, OOSTERHOF GO, THORNBURY JR, BARENTSZ JO. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR , 1996, 166, 845-852.
99. JAGER GJ, SEVERENS JL, THORNBURY JR, DE LA ROSETTE JJ, RUIJS SH, BARENTSZ JO. Prostate cancer staging: should MR imaging be used ? A decision analytic approach. Radiology, 2000, 215, 445-451.
100. JAKOBSEN J. A., CORREAS J-M. Ultrasound contrast agents and their use in urogenital radiology : status and prospects. Eur. Radiol. , 2001, 11, 2082-2091.
101. KANAMARU H, OYAMA N, AKINO H, OKADA K. Evaluation of prostate cancer using FDG-PET. Hinyokika Kiyo., 2000, 46,851-813.
102. KELLY IM, LEES WR, RICKARDS D. Prostate cancer and the role of color Doppler US. Radiology. 1993 189, 153-156.
103. KINDRICK AV, GROSSFELD GD, STIER DM, FLANDERS SC, HENNING JM, CARROLL PR : Use of imaging tests for staging newly diagnosed prostate cancer: trends from the CaPSURE database. J. Urol., 1998, 160,2102-2106.
104. KOTZERKE J, VOLKMER BG, GLATTING G, VAN DEN HOFF J, GSCHWEND JE, MESSER P, RESKE SN, NEUMAIER B. : Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin, 2003, 42, 25-30.
105. KOUTCHER JA, ZAKIAN K, HRICAK H. Magnetic resonance spectroscopic studies of the prostate. Mol. Urol., 2000, 4, 143-152.
106. KRAMER S, GORICH J, GOTTFRIED HW, RISKA P, ASCHOFF AJ, RILINGER N, BRAMBS HJ , SOKIRANSKI R. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br. J. Radiol. ,1997, 70, 995-999.
107. KULIGOWSKA E, BARISH MA, FENLON HM, BLAKE M. Predictors of prostate carcinoma : accuracy of gray-scale and color Doppler US and serum markers. Radiology, 2001, 220, 757-764.
108. KURHANEWICZ J, SWANSON MG, NELSON SJ, VIGNERON DB. : Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magn. Reson. Imaging, 2002, 16, 451-463 .
109. KURHANEWICZ J, VIGNERON DB, MALES RG, SWANSON MG, YU KK, HRICAK H. The prostate : MR imaging and spectroscopy. Present and future. Radiol. Clin. North Am .,2000, 38, 115-138.
110. LAVOIPIERRE AM, SNOW RM, FRYDENBERG M, GUNTER D, REISNER G, ROYCE PL, LAVOIPIERRE GJ. Prostatic cancer: role of color Doppler imaging in transrectal sonography. AJR Am J Roentgenol. 1998 , 171, 205-210.
111. LE BASTARD, GRENIER N, DEMINIERE C, DOUWS C, BALLANGER P, LE GUILLOU M, BROUSSIN J. Cancer localisé de la prostate : IRM et corrélations histopathologiques. Rev. Im. Med., 1990, 2, 523-530.
112. LEVENTIS A.K., SHARIAT S. F.., SLAWIN K.M. Local Recurrence after Radical Prostatectomy: Correlation of US Features with Prostatic Fossa Biopsy Findings. Radiology, 2001, 219, 432-439.
113. LILE R, THICKMAN D, MILLER GJ, CRAWFORD ED. Prostatic comedocarcinoma : correlation of sonograms with pathologic specimens in three cases. AJR , 1990,155, 303-306.
114. LIU IJ, ZAFAR MB, LAI YH, SEGALL GM, TERRIS MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology, 2001, 57, 108-111.
115. LORENZEN J, SINKUS R, ADAM G. Elastography: Quantitative imaging modality of the elastic tissue properties. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. 2003,175, 623-630.
116. MANYAK MJ, JAVITT MC. The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. Semin Urol Oncol , 16, 145-152
117. MANZONE TA, MALKOWICZ SB, TOMASZEWSKI JE, SCHNALL MD, LANGLOTZ CP. Use of endorectal MR imaging to predict prostate carcinoma recurrence after radical prostatectomy Radiology, 1998, 209, 537-542.
118. MATHEWS D, OZ OK. : Positron emission tomography in prostate and renal cell carcinoma. Curr. Opin. Urol., 2002, 12, 381-385.
119. MAY F, TREUMANN T, DETTMAR P, HARTUNG R, BREUL J. Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography in the staging of clinically localized prostate cancer. BJU, 2001, 87, 66-69.
120. MC SCHERRY SA, LEVY F, SCHIEBLER ML, KEEFE B, DENT GA, MOHLER JL. Preoperative prediction of pathological tumor volume and stage in clinically localized prostate cancer : comparison of digital rectal examination, transrectal ultrasonography and magnetic resonance imaging. J. Urol. 1991, 146, 85-89.
121. MCCAULEY TR, RIFKIN MD, LEDET CA. Pelvic lymph node visualization with MR imaging using local administration of ultra-small superparamagnetic iron oxide contrast. J. Magn. Reson. Imaging 2002, 15, 492-497.
122. MIROWITZ SA, BROWN JJ, HEIKEN JP. Evaluation of the prostate and prostatic carcinoma with gadolinium enhanced endorectal coil MR imaging. Radiology, 1993, 186, 153-157.
123. MIZOWAKI T, COHEN GN, FUNG AY, ZAIDER M. Towards integrating functional imaging in the treatment of prostate cancer with radiation: the registration of the MR spectroscopy imaging to ultrasound/CT images and its implementation in treatment planning. Int. J. Radiat. Oncol. Biol. Phys., 2002, 1;54, 1558-1564.
124. MORRIS MJ, AKHURST T, OSMAN I, NUNEZ R, MACAPINLAC H, SIEDLECKI K, VERBEL D, SCHWARTZ L, LARSON SM, SCHER HI. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002, 59, 913-918.
125. MOSKALIK AP, RUBIN MA, WOJNO KJ, BREE R.RUBIN JM, FOWLKES JB MONTIE JE, MANLEY S, CARSON PL. Analysis of three-dimensional Doppler ultrasonographic quantitative measures for the discrimination of prostate cancer. J.Ultrasound Med., 2001, 20, 713-722.
126. MOUL JW, KANE CJ, MALKOWICZ SB. The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. Urol. Clin. North Am., 2001, 28, 459-472.
127. MURPHY GP, ELGAMALAA, TROYCHAK MJ, KENNY GM. : Follow-up ProstaScint scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy. Prostate, 2000, 1, 42, 315-317.
128. NEWMAN JS, BREE RL, RUBIN JM. Prostate cancer: diagnosis with color Doppler sonography with histologic correlation of each biopsy site. Radiology, 1995, 195, 86-90.
129. NORBERG M, EGEVAD L, HOLMBERG L, SPAREN P, NORLEN BJ, BUSCH C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology, 1997, 50, 562-566.
130. NORBERG M, HÄGGMAN M, ANDERSSON T, BUSCH C, MAGNUSSON A. Evaluation of localised prostate cancer : a comparative study of transrectal ultrasonography versus histopathology. Eur. Radiol., 1993, 3, 166-173.
131. NUNEZ R, MACAPINLAC HA, YEUNG HW, AKHURST T, CAI S, OSMAN I, GONEN M, RIEDELE, SCHER HI, LARSON SM. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med., 2002, 43, 46-55.
132. OGURA K, MAEKAWA S, OKUBO K, AOKI Y, OKADA T, ODA K, WATANABE Y, TSUKAYAMA C, ARAI Y. Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. Urology, 2001, 57, 721-726.
133. OKIHARA K, KOJIMA M, NAKANOUCHI T, OKADA K, MIKI T. Transrectal power Doppler imaging in the detection of prostate cancer. BJU Int. 2000, 85, 1053-1057.
134. OUTWATER EK, PETERSEN RO, SIEGELMAN ES, GOMELLA LG, CHERNESKY CE, MITCHELL DG. Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology. 1994 , 193, 333-339.
135. OYAMA NOBUYUKI, AKINO HIRONOBU, KANAMARU HIROSHI, SUZUKI YUJI, MURAMOTO SATOSHI, YONEKURA YOSHIHARU, SADATO NORIHIRO, YAMAMOTO KAZUTAKA, OKADA KENICHIRO : 11C-Acetate PET Imaging of Prostate Cancer. J. Nuclear Med., 2002, 43 ,181-186.
136. OYEN RH. Dynamic contrast-enhanced MRI of the prostate: is this the way to proceed for characterization of prostatic carcinoma? Eur Radiol., 2003, 13,921-924.
137. OYEN WJ, WITJES JA, CORSTENS FH. Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma. Eur. Urol. 2001, 40, 294-299.
138. PARIENTE J.L. JACOB F., TRILLAUD H., DEMINIERE C., KHAN H, FERRIERE JM. , GRENIER N., LE GUILLOU M. Valeur de l'IRM endorectale dans la stadification du cancer de prostate avancé. 1997. Prog. Urol., 7, 449-454.
139. PARTIN AW, KATTAN MW, SUBONG EN, WALSH PC, WOJNO KJ, OESTERLING JE, SCARDING PT, PEARSON JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA, 1997, 14, 277, 1445-1451.
140. PARTIN AW, MANGOLD LA, LAMM DM, WALSH PC, EPSTEIN JI, PEARSON JD. Contemporary update of prostate cancer staging nomograms (partin tables) for the new millennium. Urology, 2001, 58, 843-848
141. PATEL U, RICKARDS D. The diagnostic value of colour Doppler flow in the peripheral zone of the prostate, with histological correlation Br J Urol. , 1994 , 74, 590-595.
142. PERROTTI M, HAN KR, EPSTEIN RE, KENNEDY EC, RABBANI F, BADANI K, PANTUCK AJ, WEISS RE, CUMMINGS KB. Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy : a pilot study. J. Urol. 1999, 162, 1314-1317.
143. PEYROMAURE M. Re: Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. J. Urol., 2002, 168, 1505-1506 .
144. PICCHIO M., LANDONI C., MESSA C., GIANOLLI L., MATARRESE M., DE COBELLI F., MASCHIO A., DEL FAZIO F. Positive [11C]Choline and Negative [18F]FDG with Positron Emission Tomography in Recurrence of Prostate Cancer. AJR, 2002, 179, 482-484.
145. POISSONNIER L., GELET A., CHAPELON J.Y., BOUVIER R., ROUVIERE O., PANGAUD C., LYONNET D., DUBERNARD J.M.,: Résultats du traitement par ultrasons focalisés transrectaux du cancer localisé de la prostate (120 patients avec PSA <= à 10 ng/ml). Prog Urol, 2003, 13, 60 -72.
146. PONSKY LE, CHERULLO EE, STARKEY R, NELSON D, NEUMANN D, ZIPPE CD. Evaluation of preoperative ProstaScint trade mark scans in the prediction of nodal disease. Prostate Cancer. Prostatic Dis, 2002, 5, 132-135 .
147. PRANDO A., WALLACE S. Helical CT of Prostate Cancer. AJR, 2000, 175, 343-346.
148. PRESTI JC, HRICAK H, NARAYAN PA, SHINOHARA K, WHITE S, CARROLL PR. Local staging of prostatic carcinoma : comparison of transrectal sonography and endorectal MR imaging. AJR, 1996, 166, 103-108.
149. PREZIOSI P, ORLACCHIO A, DI GIAMBATTISTA G, DI RENZI P, BORTOLOTTI L, FABIANO A, CRUCIANI E, PASQUALETTI P. Enhancement patterns of prostate cancer in dynamic MRI. Eur Radiol., 2003 , 13,925-930.
150. PUROHIT RS, SHINOHARA K, MENG MV, CAROLL PR. Imaging clinically localized prostate cancer. Urol. Clin. North Am., 2003, 30, 279-293.
151. QUINN SF, FRANZINI DA, DEMLOW TA, ROSENCRANTZ DR, KIM J, HANNA RM, SZUMOWSKI J. MR imaging of prostate cancer with endorectal surface coil technique : correlation with whole-mount specimens. Radiology, 1994, 190,323-327.
152. QUINT LE, VAN ERP JS, BLAND PH, MANDELL SH, DEL BUONO EA, GROSSMAN HB, GLAZER GM, GIKAS PW. Carcinoma of the prostate: MR images obtained with body coils do not accurately reflect tumor volume. AJR , 1991, 156 , 511-516.
153. RAJ GV, PARTIN AW, POLASCIK TJ. : Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer, 2002, 15,94, 987-996 .
154. RASCH C, BARILLOT I, REMEIJER P, TOUW A, VAN HERK M, LEBESQUE JV. Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol 1999, 1, 43, 57-66
155. RECKWITZ T, POTTER SR, PARTIN AW. Prediction of locoregional extension and metastatic disease in prostate cancer: a review. World J Urol., 2000, 18, 165-172.
156. RIETBERGEN JB, KRANSE R, KIRKELS WJ, DE KONING HJ, SCHRODER FH. Evaluation of prostate-specific antigen, digital rectal examination and transrectal ultrasonography in population-based screening for prostate cancer: improving the efficiency of early detection. Br. J. Urol., 1997, 79, 57-63.
157. RIFKIN MD, ZERHOUNI EA, GATSONIS CA, QUINT LE, PAUSHTER DM, EPSTEIN JI, HAMPER U, WALSH PC, MCNEIL BJ. Comparison of magnetic resonance imaging and ultrasonography in stating early prostate cancer. Results of a multi-institutional cooperative trial. N Engl. J. Med., 1990, 323, 621-626.
158. RIGAUD J, TIGUERT R, LE NORMAND L, KARAM G, GLEMAIN P, BUZELIN JM, BOUCHOT O. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J. Urol., 2002, 168, 1423-1426 .
159. ROGERS R, GROSSFELD GD, ROACH M 3RD, SHINOHARA K, PRESTIJC JR, CARROLL PR. Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy. J. Urol., 1998, 160, 1748-1753.
160. RORVIK J, HAUKAAS S Magnetic resonance imaging of the prostate. Curr. Opin. Urol., 2001, 11, 181-188.
161. ROUVIERE O, LYONNET D, RAUDRANT A, COLIN-PANGAUD C, CHAPELON JY, BOUVIER R, DUBERNARD JM, GELET A MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol. 2001 Sep;40(3):265-74.
162. ROUVIERE O, RAUDRANTA, ECOCHARD R, COLIN-PANGAUD C, PASQUIOU C, BOUVIER R, MARECHAL JM, LYONNET D. Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol., 2003 , 13, 931-942 .
163. SACCHETTI GM, LEVA L, INGLESE E, MONESI G, MINOCCI D, FREA B. Recent
164. SAKARYA ME, ARSLAN H, UNAL O, ATILLA MK, AYDIN S. The role of power Doppler ultrasonography in the diagnosis of prostate cancer: a preliminary study. Br J Urol. 1998 , 82, 386-368.
165. SALMINEN E, HOGG A, BINNS D, FRYDENBERG M, HICKS R. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol., 2002, 41, 425-429.
166. SANNAZZARI G L. , RAGONA R. , RUO REDDA M. G., GIGLIOLI F. R., ISOLATO G. , GUARNERI A.: CT-MRI image fusion for delineation of volumes in three-dimensional conformal radiation therapy in the treatment of localized prostate cancer. Br. J. Radiol., 2002, 75, 603-607 .
167. SAUVAIN J-L , PALASCAK P. , BOURSCHEID D. BLOQUEAU Ph, BREMON J.M. JUNG L. MANIERE Ph. Vascularisation intra-prostatique en imagerie Doppler puissance et vasculaire 3D : critères d'analyse et intérêt dans l'établissement du diagnostic et du stade évolutif des cancers. Prog. Urol., 2000,10,237-245.
168. SAVELLI G. MAFFIOLI L, MACCAURO M, DE DECKERE E, BOMBARDIERI E.: Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q. J. Nucl. Med., 2001, 45, 27-37.
169. SCHEIDLER J, HRICAK H, VIGNERON DB, YU KK, SOKOLOV DL, HUANG LR, ZALOUDEK CJ, NELSON SJ, CARROLL PR, KURHANEWICZ J. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology, 1999, 213, 473-480.
170. SEDELAAR J.P., VIJVERBERG P. L., DE REIJKER T.,.DE LA ROSETTE J. J., KIL P. J. BRAECKMAN JOHAN G, HENDRIKX J. Transrectal Ultrasound in the Diagnosis of Prostate Cancer : State of the Art and Perspectives. Eur. Urol., 2001, 40, 275-284.
171. SEDELAAR J.P.M. A, GEERT J.L.H. VAN LEENDERS B, CHRISTIAN A.HULSBERGEN-VAN DE KAA B, HENK G.VAN DER POEL A, JEROEN A.W.M. VAN DER LAAK B, DEBRUYNE F. M.J. A, WIJKSTRA H. A, JEAN DE LA ROSETTE J.M.C.H. A. Microvessel Density : Correlation between Contrast Ultrasonography and Histology of Prostate Cancer. Eur. Urol., 2001 , 40 , 285-293.
172. SEDELAAR JP, VAN LEENDERS GJ, GOOSSEN TE, HULSBERGENVAN DER KAA CA, VAN ADRICHEM NP, WIJKSTRA H, DE LA ROSETTE JJ. Value of contrast ultrasonography in the detection of significant prostate cancer: correlation with radical prostatectomy specimens. Prostate, 2002, 1,53, 246-253.
173. SEDELAAR JP, VAN ROERMUND JG, VAN LEENDERS GL, HULSBERGEN-VAN DE KAA CA, WIJKSTRA H, DE LA ROSETTE JJ. Three-dimensional grayscale ultrasound: evaluation of prostate cancer compared with benign prostatic hyperplasia. Urology, 2001, 57, 914-920
174. SELTZER SE, GETTY DJ, TEMPANY CM, PICKETT RM, SCHNALL MD, MCNEIL BJ, SWETS JA. Staging prostate cancer with MR imaging: a combined radiologist-computer system. Radiology, 1997, 202, 219-226.
175. SHIGENO K, IGAWA M, SHIINA H, WADA H, YONEDA T. The role of colour Doppler ultrasonography in detecting prostate cancer. BJU Int. 2000, ;86, 229-233.
176. SHINOHARA K., GULATI M., M.KOPIE T., TERRIS M. K. Transperineal Prostate Biopsy After Abdominoperineal Resection. J. Urol., 2003, 169, 141-144.
177. SHREVE PD, GROSSMAN HB, GROSS MD, WAHL RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F- 18]fluoro-D-glucose . Radiology, 1996, 199, 751-756 .
178. SILVERMAN JM , KREBS TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR, 1997, 168, 379-385.
179. SODEE DB, MALGURIA N, FAULHABER P, RESNICK MI, ALBERT J, BAKALE G. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology, 2000, 20, 56, 988-993.
180. SOLOWAY M, HARDEMAN SW, HICKEY D, RAYMOND J, TOBB B, SOLOWAY S, MOINUDDIN M. Stradification of patients with metastatic prostate cancer based on extend of disease on initial bone scan. Cancer, 1998, 1, 61, 195-202.
181. SOMMER FG, NGHIEM HV, HERFKENS R, MCNEAL J, LOW RN. Determining the volume of prostatic carcinoma : value of MR imaging with an external-array coil. AJR, 1993, 161, 81-86.
182. SOUCHON R, ROUVIERE O, GELET A, DETTI V, SRINIVASAN S, OPHIR J, CHAPELON JY. Visualisation of HIFU lesions using elastography of the human prostate in vivo: preliminary results. Ultrasound Med Biol., 2003, 29, 1007-1015.
183. SOULIÉ M, AZIZA R, ESCOURROU G, SEGUIN P, TOLLON C, MOLINIER L, BACHAUD JM, JOFFRE F, PLANTE P. Assessment of the risk of positive surgical margins with pelvic phased-array magnetic resonance imaging in patients with clinically localized prostate cancer : a prospective study. Urology, 2001, 58, 228-232.
184. STEINBORN MM, HEUCK AF, TILING R, BRUEGEL M, GAUGER L, REISER MF. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J. Comput. Assist. Tomogr., 1999, 23, 123-129.
185. STRANG J. G., RUBENS D. J., BRASACCHIO R. A., YU Y., MESSING E. M. Real-Time US versus CT Determination of Pubic Arch Interference for Brachytherapy. Radiology. 2001,219,387-393.
186. TAKAHASHI S, YAMADA Y, HOMMA Y, HORIE S, HOSAKA Y, KITAMURA T. Power Doppler ultrasonography-directed prostate biopsy in men with elevated serum PSA levels: an evaluation of the clinical utility and limitations. Urology, 2002 , 60, 248-252.
187. TAOKA TOSHIAKI, MAYR NINA A., LEE HAN J., YUH WILLIAM T. C., SIMONSON TERESA M., REZAI KARIM , BERBAUM KEVIN S. Factors Influencing Visualization of Vertebral Metastases on MR Imaging Versus Bone Scintigraphy. AJR, 2001,176, 1525-1530 .
188. TEMPANY CM, LANGLOTZ CP. Re: Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? J. Urol., 1997, 157, 1371-1372.
189. TEMPANY CM, ZHOU X, ZERHOUNI EA, RIFKIN MD, QUINT LE, PICCOLI CW, ELLIS JH, MCNEIL BJ. Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology. 1994 , 192, 47-54.
190. TERRIS MK, HANLY D, JOHNSTONE IM, MCNEAL JE, STAMEY TA. Prediction of prostate cancer volume using prostate specific antigen levels, transrectal ultrasound and systematic sextant biopsies. Urology 1995; 45:75-80.
191. THORNBURY J. R., ORNSTEIN D. K., CHOYKE P. L., LANGLOTZ C. P. WEINREB J. C. Prostate Cancer. What is the Future Role for Imaging. AJR, 2001 , 176,17-22.
192. TSUDA K, YU KK, COAKLEY FV, SRIVASTAV SK, SCHEIDLER JE, HRICAK H.: Detection of extracapsular extension of prostate cancer: role of fat suppression endorectal MRI. J. Comput. Assist. Tomogr., 1999, 23, 74-78.
193. TUMEH SS, BEADLE G, KAPLAN WD. Clinical significance of a solitary rib lesion in patients with extraskeletal malignancy. J. Nucl. Med, 1985, 26 , 1140-1143 .
194. UNAL D, SEDELAAR JP, AARNINK RG, VAN LEENDERS GJ, WIJKSTRA H, DEBRUYNE FM, DE LA ROSETTE JJ. Three-dimensional contrast-enhanced power Doppler ultrasonography and conventional examination methods: the value of diagnostic predictors of prostate cancer. BJU, 2000, 86, 58-64.
195. VAN HERK M, BRUCE A, KROES AP, SHOUMAN T, TOUW A, LEBESQUE JV. Quantification of organ motion during conformal radiotherapy of the prostate by three dimensional image registrations. Int J Radiat Oncol Biol Phys 1995, 1; 33, 1311-1320
196. VILANOVA JC, COMET J, CAPDEVILA A, BARCELO J, DOLZ JL, HUGUET M, BARCELO C, ALDOMA J, DELGADO E. : The value of endorectal MR imaging to predict positive biopsies in clinically intermediate-risk prostate cancer patients. Eur Radiol 2001;11(2):229-35
197. VO T., RIFKIN M.D., PETER T.L. Should ultrasound criteria of the prostate be redefined to better evaluate when and where to biopsy, Ultrasound Quarterly, 2001, 17 , 171-176.
198. WAWROSCHEK F, VOGT H, WECKERMANN D, WAGNER T, HAMM M, HARZMANN R. Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol., 2001, 166, 1715-1719.
199. WAWROSCHEK F, VOGT H, WENGENMAIR H, WECKERMANN D, HAMM M, KEIL M, GRAF G, HEIDENREICH P, HARZMANN R. Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol. Int., 2003, 70, 303-310.
200. WEFER AE, HRICAK H, VIGNERON DB, COAKLEY FV, LU Y, WEFER J, MUELLER-LISSE U, CARROLL PR, KURHANEWICZ J : Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J. Urol., 2000 , 164, 400-404.
201. WHITE S, HRICAK H, FORSTNER R, KURHANEWICZ J, VIGNERON DB, ZALOUDEK CJ, WEISS JM, NARAYAN P, CARROLL PR. Prostate cancer : effect of post biopsy hemorrhage on interpretation of MR images. Radiology, 1995, 195, 385-390.
202. YU KK, HAWKINS RA. The prostate: diagnostic evaluation of metastatic disease. Radiol. Clin. North Am., 2000, 38, 139-157.
203. YU KK, HRICAK H, ALAGAPPAN R, CHERNOFF DM, BACCHETTI P, ZALOUDEK CJ, Detection of extracapsular extension of prostate carcinoma with endorectal and phased array coil MR imaging : multivariate feature analysis . Radiology, 1997, 202, 697-702 .
204. YU KK, SCHEIDLER J., , HRICAK H., VIGNERON D. B., YU K. K., SOKOLOV D. L., HUANG L. R., ZALOUDEK C. J., NELSON S. J., CARROLL P. R., KURHANEWICZ J. Prostate Cancer: Localization with Three-dimensional Proton MR Spectroscopic Imaging-Clinicopathologic Study. Radiology, 1999, 213, 473-480.
205. ZELEFSKY MJ, FUKS Z, HUNT M, LEE HJ, LOMBARDI D, LING CC, REUTER VE, VENKATRAMAN ES, LEIBEL SA. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001 , 166, 876-881
206. ZELEFSKY MJ, LEIBEL SA, GAUDIN PB, KUTCHER GJ, FLESHNER NE, VENKATRAMEN ES, REUTER VE, FAIR WR, LING CC, FUKS Z. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998, 1, 41, 491-500